Eun Gyeong Yang

Dr. Eun Gyeong Yang


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ASAlex K. Shalek
Alex K. Shalek
JRJacob T. Robinson
Jacob T. Robinson
EKEthan S. Karp
Ethan S. Karp
JLJin Seok Lee
Jin Seok Lee
DADae-Ro Ahn
Dae-Ro Ahn
HPHongkun Park
Hongkun Park
A generalized platform for introducing a diverse range of biomolecules into living cells in high-throughput could transform how complex cellular processes are probed and analyzed. Here, we demonstrate spatially localized, efficient, and universal delivery of biomolecules into immortalized and primary mammalian cells using surface-modified vertical silicon nanowires. The method relies on the ability of the silicon nanowires to penetrate a cell’s membrane and subsequently release surface-bound molecules directly into the cell’s cytosol, thus allowing highly efficient delivery of biomolecules without chemical modification or viral packaging. This modality enables one to assess the phenotypic consequences of introducing a broad range of biological effectors (DNAs, RNAs, peptides, proteins, and small molecules) into almost any cell type. We show that this platform can be used to guide neuronal progenitor growth with small molecules, knock down transcript levels by delivering siRNAs, inhibit apoptosis using peptides, and introduce targeted proteins to specific organelles. We further demonstrate codelivery of siRNAs and proteins on a single substrate in a microarray format, highlighting this technology’s potential as a robust, monolithic platform for high-throughput, miniaturized bioassays.

1 January 2019 in Cancer Cell
Verified
Journal Article
Closed access
DMDong-Gi Mun
Dong-Gi Mun
JBJinhyuk Bhin
Jinhyuk Bhin
SKSangok Kim
Sangok Kim
HKHyunwoo Kim
Hyunwoo Kim
JJJae Hun Jung
Jae Hun Jung
DHDaehee Hwang
Daehee Hwang

20 December 2012 in Nano Letters
Verified
Journal Article
Closed access
YNYu-Ran Na
Yu-Ran Na
SKSo Yeon Kim
So Yeon Kim
JGJellert T. Gaublomme
Jellert T. Gaublomme
ASAlex K. Shalek
Alex K. Shalek
MJMarsela Jorgolli
Marsela Jorgolli
EYEun Gyeong Yang
Eun Gyeong Yang

19 November 2015 in Molecules
Verified
Journal Article
Open access
PDF file
SKSo Yeon Kim
So Yeon Kim
EYEun Gyeong Yang
Eun Gyeong Yang
Hypoxia-inducible factor (HIF) prolyl hydroxylases (PHDs) are members of the 2-oxoglutarate dependent non-heme iron dioxygenases. Due to their physiological roles in regulation of HIF-1α stability, many efforts have been focused on searching for selective PHD inhibitors to control HIF-1α levels for therapeutic applications. In this review, we first describe the structure of PHD2 as a molecular basis for structure-based drug design (SBDD) and various experimental methods developed for measuring PHD activity. We further discuss the current status of the development of PHD inhibitors enabled by combining SBDD approaches with high-throughput screening. Finally, we highlight the clinical implications of small molecule PHD inhibitors.

1 July 2008 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
HCHyunju Cho
Hyunju Cho
HLHo-Youl Lee
Ho-Youl Lee
DADae-Ro Ahn
Dae-Ro Ahn
SKSang Yoon Kim
Sang Yoon Kim
SKSunyun Kim
Sunyun Kim
EYEun Gyeong Yang
Eun Gyeong Yang
Targeting the oxygen-sensing mechanisms of the hypoxiainducible factor (HIF) pathway provides pharmacological ways of manipulating the HIF response. Because HIF-1α-specific prolyl-4 hydroxylases (PHDs) prime degradation of HIF-1α, we have made an effort to find a small molecule capable of up-regulating the HIF pathway by inhibiting prolyl hydroxylation. Through an in vitro high-throughput screen, we have discovered a PHD2 inhibitor baicalein, which is also found to abrogate asparaginyl hydroxylation of HIF-1α. Such inhibitory effects are reversed by the addition of excess 2-oxoglutarate and iron(II), suggesting the involvement of baicalein9s binding at the enzyme active sites, which has also been corroborated by spectroscopic binding assays between baicalein and enzyme. In addition, baicalein suppresses ubiquitination of HIF-1α, which works in concert with the inhibition of the HIF-specific hydroxylases to increase the HIF-1α content, leading to induction of HIF-1-mediated reporter gene activity and target gene transcription in tissue culture cells, whereas it induces HIF-independent activation of other genes. Furthermore, in vivo organ models based on the chick chorioallantoic membrane assay demonstrate that baicalein promotes new blood vessel formation. Together, our results indicate that baicalein possesses a proangiogenic potential and thus might have the therapeutic utility in the treatment of ischemic diseases.

18 April 2012 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
KHKi-Cheol Han
Ki-Cheol Han
EYEun Gyeong Yang
Eun Gyeong Yang
DADae-Ro Ahn
Dae-Ro Ahn
We describe a highly sensitive, multiplex immunoassay utilizing gold nanoparticles for conjugation of detection antibodies with signal generators. The method has been compared with conventional methods and evaluated for simultaneous detection of two different biomarkers in human serum.